NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

• ClinicalTrials.gov Identifier: NCT02379845
• Recruitment Status: Completed
• First Posted: March 5, 2015
• Last Update Posted: April 6, 2021
• Sponsor: Nanobiotix
• Collaborator: PharmaEngine
• Information provided by (Responsible Party): Nanobiotix

Tracking Information

• First Submitted Date: February 19, 2015
• First Posted Date: March 5, 2015
• Last Update Posted Date: April 6, 2021
• Actual Study Start Date: March 3, 2015
• Actual Primary Completion Date: May 22, 2018 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 1, 2015)

Pathological Complete Response Rate (pCRR) [ Time Frame: 36 months ]

To compare antitumor activity in terms of Pathological complete response rate (pCRR) of intratumor injection of NBTXR3 activated by external beam radiation therapy (EBRT), versus EBRT alone

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: October 6, 2020)

• Incidence of early and late TEAE, post-TEAE, SAE and laboratory abnormalities (NCI CTCAE V4.0) [ Time Frame: 36 months ]
• Objective Response Rate (ORR) by Imaging (MRI) according to RECIST 1.1 [ Time Frame: 36 months ]
• Tumor volume changes (theoretical tumor volume estimated as: Length x Width x Depth [ Time Frame: 36 months ]
• Resection Margins (R0, R1, R2) [ Time Frame: 36 months ]
• Hyalinization, fibrosis, necrosis and tumor infarction percentage [ Time Frame: 36 months ]
• Limb amputation rate [ Time Frame: 36 months ]

Original Secondary Outcome Measures (submitted: March 1, 2015)

• Incidence of early and late TEAE, post-TEAE, SAE and laboratory abnormalities (NCI CTCAE V4.0) [ Time Frame: 30 months ]
• Objective Response Rate (ORR) by Imaging (MRI) according to RECIST 1.1 [ Time Frame: 30 months ]
• Tumor volume changes (theoretical tumor volume estimated as: Lenght x Width x Depth [ Time Frame: 30 months ]
• Resection Margins (R0, R1, R2) [ Time Frame: 30 months ]
• Limb amputation rate [ Time Frame: 36 months ]

• Current Other Pre-specified Outcome Measures (submitted: June 1, 2018): Local and distant recurrence rate [ Time Frame: 12 months and 24 months ]
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall
• Official Title: A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall

Brief Summary

RATIONALE: Radiation therapy given before surgery of soft tissue sarcoma decreases the size of the tumor mass and the presence of malignant cells in its peripheral region. NBTXR3 and radiation therapy may kill more cancer cells and increase the tumor shrinkage rendering surgery more feasible or easier and achieve better local control of the tumor.

PURPOSE: This phase II/III is a prospective randomized, multi-center, open-label and active controlled two arms study in patients with locally advanced soft tissue sarcoma (STS) of the extremity and trunk wall. Patients will be randomized to receive either NBTXR3 as intratumor injection, activated by external beam radiation therapy or external beam radiation therapy alone, as preoperative treatment. Once the radiotherapy treatment is completed, tumor surgery will be performed in all patients.

• Detailed Description: Patients who will be allocated in arm A, will receive a single intratumor injection of NBTXR3 and will receive external beam radiotherapy starting 24hrs after the injection up to completion of 5 weeks, 5 days a week of treatment (50Gy, 2Gy/fraction). Then, all patients will undergo surgical resection of the tumor 5 weeks later and will be followed for wound healing and toxicity assessment. A visit of end of treatment will take place approximately 3-4 weeks after surgery. Patients will be followed for evaluation of their disease status and adverse event until the end of study.
• Study Type: Interventional
• Study Phase: Phase 2; Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Adult Soft Tissue Sarcoma

Intervention

• Device: NBTXR3
  One intratumor implantation by injection
  Other Name: PEP503
• Device: Radiation therapy
  5 weeks/50 Gy (5 x 2 Gy by week)

Study Arms

• Experimental: Arm A
  NBTXR3 + Radiotherapy
  Interventions:

  • Device: NBTXR3
  • Device: Radiation therapy
• Active Comparator: Arm B
  Radiotherapy alone
  Intervention: Device: Radiation therapy

• Publications *: Bonvalot S, Rutkowski PL, Thariat J, Carrere S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baere T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Verges R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovee JVMG, Le Pechoux C, Papai Z. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8. Erratum In: Lancet Oncol. 2019 Sep;20(9):e468.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: March 1, 2015): 180
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: September 20, 2020
• Actual Primary Completion Date: May 22, 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Age: 18 years and older
• Locally Advanced Soft Tissue Sarcoma of the Extremity and Trunk Wall
• All grades

• Candidate to radiotherapy + surgery (ESMO guideline 2014) i.e. tumor must not have involvement of bone and / or vessel and or nerve :

  • Primary tumor or,
  • Relapsed tumor, localized out of previously irradiated area
• WHO performance score 0 to 2
• Adequate function of bone marrow
• Adequate renal function
• Adequate hepatic function
• Adequate pulmonary function
• All female patients of childbearing potential must have a negative serum/urinary pregnancy test

Exclusion Criteria:

• Absence of written Informed Consent duly signed and dated
• Patients with the following histological type: embryonal or alveolar rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma or chondrosarcoma, Kaposi's sarcoma, primitive neuroectodermal tumor, angiosarcoma, aggressive fibromatosis or dermatofibrosarcoma protuberans
• Soft Tissue Sarcoma of the Trunk Wall localized in the abdominal region i.e. the region defined cranially by the xiphoid process of the sternum and the costal margins, and caudally by the line joining the anterior superior iliac spines, both limited by the perpendicular lines crossing both nipples
• Patient with a calculated tumor baseline volume > 3000 mL
• Metastatic disease (CT-scan / MRI verification) with life expectancy shorter than 6 months
• Previous radiation therapy in relapse site of soft tissue sarcoma (no radiation re-challenge is permitted)
• Concurrent treatment with any other anticancer therapy, including chemotherapy, immunotherapy, targeted therapy, gene therapy, or patients planning to receive these treatments during the study
• Absence of histologically or cytologically proven cancer at the first diagnosis
• Previous neoadjuvant chemotherapy treatment given as an upfront of the current treatment line
• Hemolytic anemia
• Autoimmune disease
• Complete initial work up earlier than 4 weeks prior to patient registration
• Patients unable to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
• Patients participating in another clinical investigation at the time of signature of the informed consent

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Belgium, France, Germany, Hong Kong, Hungary, Italy, Norway, Philippines, Poland, Romania, South Africa, Spain
• Removed Location Countries: Canada, Netherlands

Administrative Information

• NCT Number: NCT02379845
• Other Study ID Numbers: NBTXR3-301
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Nanobiotix
• Original Responsible Party: Same as current
• Current Study Sponsor: Nanobiotix
• Original Study Sponsor: Same as current
• Collaborators: PharmaEngine
• Investigators: Not Provided
• PRS Account: Nanobiotix
• Verification Date: April 2021